Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Change in Account Payables: 2017-2025

Historic Change in Account Payables for Protagonist Therapeutics (PTGX) over the last 9 years, with Sep 2025 value amounting to $2.4 million.

  • Protagonist Therapeutics' Change in Account Payables rose 781.13% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 55.22%. This contributed to the annual value of $842,000 for FY2024, which is 129.36% up from last year.
  • Latest data reveals that Protagonist Therapeutics reported Change in Account Payables of $2.4 million as of Q3 2025, which was up 544.80% from $375,000 recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Change in Account Payables registered a high of $5.6 million during Q1 2022, and its lowest value of -$10.9 million during Q3 2021.
  • In the last 3 years, Protagonist Therapeutics' Change in Account Payables had a median value of $375,000 in 2025 and averaged $182,182.
  • Its Change in Account Payables has fluctuated over the past 5 years, first plummeted by 1,119.46% in 2021, then surged by 781.13% in 2025.
  • Over the past 5 years, Protagonist Therapeutics' Change in Account Payables (Quarterly) stood at $452,000 in 2021, then slumped by 338.05% to -$1.1 million in 2022, then surged by 44.52% to -$597,000 in 2023, then slumped by 139.53% to -$1.4 million in 2024, then spiked by 781.13% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q3 2025, $375,000 for Q2 2025, and $1.2 million during Q1 2025.